---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-039357"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:02:54.901146+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst Biosciences provides H1 2023 financials of target Beijing Continent; revenue up 21% YoY

## Summary
- BC revenue RMB379.3M, net profit RMB81.2M for H1 2023 vs revenue RMB312.7M, net profit RMB63.9M in H1 2022.
- BC main product ETUARY for idiopathic pulmonary fibrosis; gross margin 96% in H1 2023.
- BC total assets RMB806.6M, equity RMB707.8M as of June 30, 2023.
- Catalyst's acquisition of indirect controlling interest in BC subject to stockholder approval; proxy mailed July 20, 2023.

## SEC filing metadata
- accession: 0001140361-23-039357
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123039357/0001140361-23-039357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123039357/brhc20056996_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-039357
- JSON: https://secwatch.observer/filing/0001140361-23-039357.json
- Plain text: https://secwatch.observer/filing/0001140361-23-039357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.